Rep. Michael A. Rulli Sells Off Eli Lilly and Company (NYSE:LLY) Shares

Key Points

• Rep. Michael A. Rulli sold between $1,001 and $15,000 of Eli Lilly shares on July 1 through a Merrill Lynch managed account. He also recently sold Crown Castle and Microsoft shares while purchasing stocks including KLA, Alphabet, Micron and NVIDIA.
• Eli Lilly shares opened at $1,230, up 3.7%, after the company reported quarterly EPS of $8.38 versus the $6.40 consensus and revenue growth of 47.7% to $22.97 billion. Management issued fiscal 2026 EPS guidance of $35.50 to $36.50.
• Analysts maintain a broadly positive outlook, with a consensus “Moderate Buy” rating and an average price target of $1,292.18. Lilly also declared a quarterly dividend of $1.73 per share, while an executive separately sold $5.95 million of stock under a pre-arranged trading plan.

Representative Michael A. Rulli (Republican-Ohio) recently sold shares of Eli Lilly and Company NYSE: LLY. In a filing disclosed on August 07th, the Representative disclosed that they had sold between $1,001 and $15,000 in Eli Lilly and Company stock on July 1st. The trade occurred in the Representative's "MERRILL LYNCH MANAGED ACCOUNT" account.

Representative Michael A. Rulli also recently made the following trade(s):

• Sold $1,001 - $15,000 in shares of Crown Castle NYSE: CCI on 8/6/2026.
• Purchased $1,001 - $15,000 in shares of KLA NASDAQ: KLAC on 7/1/2026.
• Purchased $1,001 - $15,000 in shares of Alphabet NASDAQ: GOOGL on 6/29/2026.
• Purchased $1,001 - $15,000 in shares of Micron Technology NASDAQ: MU on 6/25/2026.
• Purchased $1,001 - $15,000 in shares of Alphabet NASDAQ: GOOGL on 6/25/2026.
• Sold $1,001 - $15,000 in shares of Microsoft NASDAQ: MSFT on 6/25/2026.
• Purchased $1,001 - $15,000 in shares of NVIDIA NASDAQ: NVDA on 6/25/2026.
• Sold $1,001 - $15,000 in shares of Amazon.com NASDAQ: AMZN on 6/25/2026.
• Sold $1,001 - $15,000 in shares of Apple NASDAQ: AAPL on 6/25/2026.

Eli Lilly and Company Stock Up 3.7%

Shares of NYSE LLY opened at $1,230.00 on Tuesday. Eli Lilly and Company has a 1 year low of $625.90 and a 1 year high of $1,249.45. The firm's 50-day moving average is $1,162.38 and its 200-day moving average is $1,048.95. The company has a current ratio of 1.35, a quick ratio of 1.00 and a debt-to-equity ratio of 1.41. The firm has a market capitalization of $1.16 trillion, a PE ratio of 41.28, a price-to-earnings-growth ratio of 1.38 and a beta of 0.51.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last posted its quarterly earnings results on Wednesday, August 5th. The company reported $8.38 earnings per share for the quarter, topping analysts' consensus estimates of $6.40 by $1.98. Eli Lilly and Company had a net margin of 33.53% and a return on equity of 97.83%. The business had revenue of $22.97 billion during the quarter, compared to the consensus estimate of $20.82 billion. During the same period in the previous year, the firm posted $6.31 earnings per share. Eli Lilly and Company's revenue for the quarter was up 47.7% compared to the same quarter last year. Eli Lilly and Company has set its FY 2026 guidance at 35.500-36.500 EPS. Equities analysts expect that Eli Lilly and Company will post 36.77 EPS for the current year.

Eli Lilly and Company Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Thursday, September 10th. Stockholders of record on Friday, August 14th will be paid a $1.73 dividend. This represents a $6.92 annualized dividend and a dividend yield of 0.6%. The ex-dividend date of this dividend is Friday, August 14th. Eli Lilly and Company's dividend payout ratio (DPR) is 23.22%.

Analyst Upgrades and Downgrades

Several analysts have commented on LLY shares. Leerink Partners upped their target price on shares of Eli Lilly and Company from $1,119.00 to $1,232.00 and gave the company an "outperform" rating in a research report on Thursday, June 25th. Cantor Fitzgerald increased their target price on Eli Lilly and Company from $1,350.00 to $1,410.00 and gave the company an "overweight" rating in a research note on Thursday, August 6th. Royal Bank Of Canada raised their target price on Eli Lilly and Company from $1,250.00 to $1,500.00 and gave the stock an "outperform" rating in a report on Wednesday, July 8th. JPMorgan Chase & Co. boosted their target price on Eli Lilly and Company from $1,300.00 to $1,400.00 and gave the stock an "overweight" rating in a research report on Tuesday, July 7th. Finally, Wall Street Zen lowered shares of Eli Lilly and Company from a "strong-buy" rating to a "buy" rating in a report on Saturday, July 18th. Two investment analysts have rated the stock with a Strong Buy rating, twenty-four have issued a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average target price of $1,292.18.

Insider Activity at Eli Lilly and Company

In related news, EVP Anat Hakim sold 5,000 shares of the company's stock in a transaction dated Friday, August 7th. The shares were sold at an average price of $1,190.00, for a total value of $5,950,000.00. Following the transaction, the executive vice president owned 11,875 shares in the company, valued at approximately $14,131,250. This represents a 29.63% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 0.14% of the company's stock.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of LLY. Vanguard Group Inc. raised its holdings in Eli Lilly and Company by 1.2% during the fourth quarter. Vanguard Group Inc. now owns 81,965,974 shares of the company's stock worth $88,087,193,000 after acquiring an additional 1,006,885 shares in the last quarter. BlackRock Inc. boosted its stake in shares of Eli Lilly and Company by 1.6% during the 2nd quarter. BlackRock Inc. now owns 67,540,400 shares of the company's stock worth $81,009,981,000 after acquiring an additional 1,046,558 shares during the period. State Street Corp increased its holdings in shares of Eli Lilly and Company by 1.8% during the 4th quarter. State Street Corp now owns 35,361,916 shares of the company's stock worth $38,002,744,000 after acquiring an additional 635,358 shares during the last quarter. Morgan Stanley raised its position in shares of Eli Lilly and Company by 2.7% in the fourth quarter. Morgan Stanley now owns 15,593,019 shares of the company's stock valued at $16,757,510,000 after purchasing an additional 407,166 shares during the period. Finally, Capital World Investors raised its position in shares of Eli Lilly and Company by 0.4% in the fourth quarter. Capital World Investors now owns 15,031,750 shares of the company's stock valued at $16,154,619,000 after purchasing an additional 61,851 shares during the period. 82.53% of the stock is currently owned by institutional investors.

Eli Lilly and Company News Roundup

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: The U.K. Medicines and Healthcare products Regulatory Agency approved Lilly’s Foundayo for weight loss and weight maintenance in certain adults with obesity or overweight-related health conditions. The authorization is the pill’s first European approval and gives Lilly access to a large potential market supported by its global commercial infrastructure. Eli Lilly’s GLP-1 Pill Secures First European Milestone
• Positive Sentiment: The approval also strengthens Lilly’s competitive position against Novo Nordisk in obesity drugs. Analysts and investors are increasingly focused on whether a convenient oral treatment can expand the GLP-1 market and increase patient adoption. Why Eli Lilly Topped the Market Today
• Positive Sentiment: Lilly’s latest quarterly performance remains a major support for the stock. Second-quarter revenue rose 47.7% year over year to approximately $23.0 billion, while adjusted EPS of $8.38 exceeded the $6.40 consensus estimate. Management set fiscal 2026 EPS guidance of $35.50 to $36.50, highlighting continued confidence in demand for its portfolio. Eli Lilly Posts Blowout Growth and Raises Its Outlook
• Neutral Sentiment: Investors are also weighing potential U.S. policies encouraging domestic pharmaceutical manufacturing. Lilly may be relatively well positioned if reshoring requirements favor companies with significant U.S. production capacity, although the policy details and costs remain uncertain. Eli Lilly vs. Novo Nordisk
• Neutral Sentiment: Sector rotation toward innovative healthcare companies, as investors seek alternatives to highly valued technology stocks, provided an additional supportive backdrop for Lilly. Jim Cramer Highlights Pharmaceutical Giants
• Negative Sentiment: Executive Vice President Anat Hakim sold 5,000 shares worth approximately $5.95 million under a pre-arranged Rule 10b5-1 trading plan. The transaction may attract attention, but its scheduled nature reduces its significance as a signal about Lilly’s outlook. SEC Form 4 Filing

About Representative Rulli

Michael Rulli (Republican Party) is a member of the U.S. House, representing Ohio's 6th Congressional District. He assumed office on June 25, 2024. His current term ends on January 3, 2027. Rulli (Republican Party) is running for re-election to the U.S. House to represent Ohio's 6th Congressional District. He declared candidacy for the 2026 election. Michael Rulli graduated from Poland Seminary High School. He earned a degree from Emerson College. Rulli's career experience includes working as the director of operations with Rulli Bros. Markets.

Eli Lilly and Company Company Profile

Eli Lilly and Company NYSE: LLY is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source